Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Hospira, Inc.

Latest From Hospira, Inc.

The Future Of Medicine: Cell And Gene Therapies Take The Lead

BIO panel with Roche’s James Sabry, Spark’s Federico Mingozzi and Adaptive’s Harlan Robins imagines a world where cell and gene therapies are preferred over small molecules and antibodies.

Innovation Regenerative Medicine

Finance Watch: Erasca Raises $200m As VC Mega-Rounds Continue

Private Company Edition: In addition to Erasca’s big series B round, Mabwell reportedly brought in $278m. Also, Kurma, Venrock and Section bring the number of new VC funds in April to eight, raising $5.89bn, and former AveXis execs launched the new gene therapy venture Taysha.

Financing Innovation

Hospira Will Not Be Reheard On Retacrit Biosimilar

Hospira has been frustrated again in long-running litigation concerning its Retacrit biosimilar to Amgen’s Epogen, in a case closely watched by the biopharma industry as it addressed what constitutes a safe harbor for a biosimilar applicant.

Intellectual Property Biosimilars

Celltrion And Pfizer Cement Victory On Infliximab

Celltrion and Pfizer are now two for two in their legal battles with Janssen over US patents shielding the originator's Remicade (infliximab), with a US Court of Appeals once again siding with the biosimilars developers.

Legal Issues Intellectual Property
See All

Company Information

  • Other Names / Subsidiaries
    • Javelin Pharmaceuticals, Inc.
    • Mayne Pharma Limited